Introduction
Hypertension is a major risk factor of cardiovascular morbidity and mortality in China and worldwide.13 According to the China Hypertension Survey,4 the number of adults with hypertension is nearly 245 million. Elevated blood pressure (BP) causes left ventricular (LV) structural and functional alteration, which predisposes hypertensive patients developing heart failure.5,6 Therefore, evaluating LV structure and function is important to predict the prognosis for hypertensive populations.
Prior studies have reported the relationship between BP and parameters of LV structure and function based on office BP (OBP).711 The association between 24h ambulatory blood pressure (ABP) and LV structure and function was less investigated. In addition, participants of these studies were almost White populations, and data on the Chinese population are remarkably limited. Numerous studies have reported racial and ethnic disparities in cardiac remodeling.12,13 Therefore, it is clinically relevant to evaluate the association between BP and LV structure and function in Chinese hypertensive patients, considering the increasing prevalence of hypertension and associated health complication in China.14,15
Several studies have reported the sex-differences in LV structural and functional alteration with elevated OBP.1618 However, whether there were differences in the association between 24h ABP and LV structural and functional alteration by sex was undetermined. Herein, we conducted a retrospective study to evaluate the association of OBP and 24h ABP with LV structure and function in hypertensive patients without overt cardiovascular diseases. In addition, we evaluated whether the association was modified by sex.
The current study was approved by the Institution Review Board of the Huizhou Municipal Central Hospital. Since this was a retrospective study, no consent form was obtained, and the Ethnic Committee of Huizhou Municipal Central Hospital waived the consent form. Patients data were keeping confidentiality and all the performances were in accordance with the Declaration of Helsinki.19 Hypertensive patients in the inpatient clinic of our hospital between July 2019 and July 2021 were screened for the eligibility of the current study. The inclusion criteria were as follows: hypertensive patients who 1) were receiving antihypertensive drug; 2) had transthoracic echocardiographic examination in recent 1 month of index inpatient visit; and 3) had 24h ABP measurements in recent 1 month of index inpatient visit. The exclusion criteria were as follows: 1) documented secondary hypertension and 2) documented cardiovascular disease, including coronary heart disease, myocardial infarction, ischemic stroke, intracranial hemorrhage, heart failure, valvular heart disease, hypertrophy, dilated or restrictive cardiomyopathy, myocarditis, congenital heart disease, pulmonary hypertension, or pericardial disease.
Transthoracic echocardiographic parameters were extracted from electronic health record of inpatient clinic system. Parameters used in the current analysis included left atria diameter (LAd), LV end systolic and diastolic diameter (LVESd and LVEDd), LV mass index (LVMi), relative wall thickness (RWT), LV ejection fraction (LVEF), lateral mitral annular diastolic velocity e, and E/e ratio. Specifically, RWT = (posterior wall thickness [PWT] + interventricular septal thickness [IVST])/LVEDd. LV mass (LVM)=0.8*[1.04 *([LVEDd + IVST + PWT] 3 LVEDd3)] + 0.6 and LVMi=LVM/body surface area (BSA). LVMi 115 g/m2 for men and 95 g/m2 for women were defined as LV hypertrophy (LVH). Based on the value RWT of (0.42 or >0.42) and the presence of LVH, LV geometry was classified into normal (RWT 0.42 and LVH absence), concentric remodeling (RWT > 0.42 and LVH absence), concentric hypertrophy (RWT > 0.42 and LVH presence), and eccentric hypertrophy (RWT 0.42 and LVH presence), respectively.20
BP parameters were extracted from medical health record in the clinic system. In brief, according to the China Hypertension Guideline, OBP was measured two times with 1-minute interval and the average value of these two BP readings was used. If the first two BP readings differed by more than 10 mm Hg, the third measurement was performed and the average of the three readings was used. Parameters of 24h ABP included daytime, nighttime and 24h systolic and diastolic BP (SBP and DBP). Patients with a nighttime-to-daytime ratio of SBP and/or DBP 0.90 were defined as having a dipping pattern, and those with a ratio >0.90 were defined as having a non-dipping pattern, and those with nighttime BP higher than daytime BP was defined as reverse dipper.21
Structured questionnaire was used to collect data at baseline. Data, which included demographics (age and sex), anthropometrics (body weight and height), comorbidities (smoking, obesity, dyslipidemia, diabetes mellitus and obstructive sleep apnea), laboratory and medications used, were collected by two independent investigators. Body mass index (BMI) was calculated as Weight/Height2, and BMI 28 kg/m2 was defined as obesity for Chinese populations,22 and BSA was calculated as (Weight 0.425 * Height 0.725) * 0.007184.
Continuous variables were presented as mean standard deviation (SD) and between-group differences were assessed using Student t-test, and categorical variables were presented as number (percentage) and between-group differences were assessed by Chi-Square test or Fishers exact test. Linear regression analysis was performed to evaluate the association between per 1-SD change of OBP and 24h ABP with LVMi and e velocity with adjustment for potential covariates including age, obesity, diabetes mellitus, obstructive sleep apnea, estimated glomerular filtration rate (eGFR) and antihypertensive drugs. Multivariable regression analysis was performed to evaluate the association between per 1-SD change of OBP and 24h ABP with LVH, with adjustment for covariates including age, obesity, diabetes mellitus, obstructive sleep apnea, eGFR and antihypertensive drugs. These associations were also assessed by sex and a P-value for interaction was reported. All the statistical analyses were performed using SPSS 23.0 package and a two-sided P value <0.05 was considered as statistical significance.
A total of 694 patients were enrolled for the current analysis (Figure 1). Baseline characteristics of all participants are presented in Table 1. The mean age was 62.9 years and women accounted for 36.3%. Compared to men, women were younger and less likely to smoke, had a higher triglyceride level, and were less likely to receive calcium channel blocker and more likely to receive beta-blocker.
Table 1 Baseline Characteristics
Figure 1 Study flowchart.
As presented in Table 2, 37.2% of the participants had LVH, and among these participants, 25.2% and 12.0% had concentric and eccentric LVH, respectively. Compared to men, women had a smaller LVESd and LVEDd and LVMi. In addition, women were less likely to have concentric LVH (8.3% vs 14.0%) while they had a higher e velocity (9.5 cm vs 9.0 cm).
Table 2 Echocardiographic Parameters
As shown in Table 3, there was no difference in office SBP and DBP between men and women. However, compared to women, men had a higher 24h (132.6 11.3 vs 129.3 10.0 mm Hg), daytime (136.6 12.9 vs 132.8 9.5 mm Hg) and nighttime (130.3 9.2 vs 125.1 6.6 mm Hg) SBP. There was no difference in 24h, daytime and nighttime DBP by sex. In addition, the proportion of patients with non-dipping (34.6% vs 29.0%) and reverse dipper pattern (16.7% vs 11.9%) was also higher in men than in women.
Table 3 Parameters of OBP and 24h ABP
In the overall participants, 24h, daytime and nighttime SBP, non-dipping and reverse dipper pattern were significantly associated with LVMi and e velocity, and no association was observed in OBP (Table 4). The magnitude of the association between 24h, daytime and nighttime SBP, non-dipping and reverse dipper pattern with LVMi was stronger in men than in women (P-value for interaction <0.05), as was e velocity (P-value for interaction <0.05). Notably, there was no association between 24h, daytime and nighttime DBP with LVMi and e velocity.
Table 4 Association Between OBP and 24h ABP with LVMi and e Velocity
In the overall participants, 24h, daytime and nighttime SBP, and non-dipping and reverse dipper pattern were significantly associated with LVH, and no association was observed in OBP (Table 5). The magnitude of the association between 24h, daytime and nighttime SBP, non-dipping and reverse dipper pattern with LVH was stronger in men than in women (P-value for interaction <0.05). However, there was no association between 24h, daytime and nighttime DBP with LVH.
Table 5 Association Between OBP and 24h ABP with LVH
The current study, to the best of our knowledge, should be the first few studies to evaluate the association between 24h ABP and the LV structure and function in hypertensive patients without cardiovascular disease. There are three important findings. First, compared to OBP, 24h ABP appears to be more closely associated with LV structure and function. Second, among 24h ABP parameters, only 24h, daytime and nighttime SBP were associated with LV structure and function after adjusted for multiple covariates. Third, the magnitude of these associations was stronger in men than in women.
There are three potentially clinically important implications of the current study. First of all, compared to OBP, 24h ABP provided additional valuable information in assessing the association between elevated BP and LV structural and functional alterations, suggesting that 24h ABP parameters could provide additional information for prognostic assessment. It might be appropriate to apply 24h ABP for hypertensive patients with high cardiovascular risk in daily clinical practice. Second, SBP was better than DBP in terms of their correlations with LV structural and functional alterations. These findings demonstrate that ambulatory SBP might be more relevant than ambulatory DBP to assess the association between elevated ABP and LV structure and function. Third, elevated ambulatory SBP had stronger effects on LV structural and functional alteration in men than in women, indicating that men might require more intensive SBP lowering than their female counterparts to prevent LV structural and functional alteration.
Numerous studies have evaluated the association between elevated OBP with LV structure and function. For example, Lauer et al reported that in the Framingham Heart Study, 30-year average office DBP was correlated with LVM but to a lesser degree than office SBP.23 Savage et al reported that office SBP was associated with LVM in both sexes.24 Based on OBP, Cuspidi et al classified participants into normotension, prehypertension and hypertension. After 10 years follow-up, they found that the incidence of LVH increased progressively from the normotensive to prehypertension and hypertension group (9.0%, 23.2%, and 36.5%, respectively).25 Li et al recently evaluated the cardiac and vascular responses to elevated OBP in Chinese populations without cardiovascular disease.16 The results suggest that LV structural and functional alteration was stronger in women than in men. Cai et al evaluated the age-related LV structural and functional alteration by sex in different office SBP level.7 The results suggest that lower office SBP level attenuated the sex-difference in LV structural and functional alterations with age. These results demonstrate the effects of elevated OBP on LV structural and functional alteration.26
Compared to OBP, 24h ABP can provide additional information on BP assessment outside of office. For example, OBP only assesses BP in the clinic, while 24h ABP is useful to evaluate BP around the day. In addition, 24h ABP provides information on nighttime BP during sleep, and the daytime and nighttime BP ratio can be used to determine the BP pattern, which has been associated with prognosis.2729 Despite these advantages, 24h ABP has not been routinely used for all hypertensive patients in daily clinical practice due to the cost and feasibility in many remote areas. In the current study, we retrospectively evaluated the association between OBP and 24h ABP with LV structure and function in hypertensive patients without cardiovascular diseases. Our results indicated that only 24h SBP was associated with LVMi and e velocity. In addition, daytime and nighttime SBP, non-dipping and reverse dipper pattern were associated with LVMi and e velocity. Notably, the -coefficient was larger in 24h, daytime and nighttime SBP compared to office SBP, suggesting that 24h ABP might be more closely related to LV structural and functional alteration than OBP. In addition, when evaluating the association by sex, there was no significant interaction in office SBP. However, in 24h, daytime and nighttime SBP, the association with LVMi and e velocity was stronger in men than in women. We then evaluated the association between OBP and 24h ABP with LVH, and the findings were consistent with above results. Taken together, these findings demonstrate that 24h ABP provided additional value in evaluating the influence of elevated BP on LV structural and functional alteration in hypertensive patients. Further studies are needed to corroborate the current findings.
There are some limitations of the current study. First, this was a retrospective study, and the findings cannot be drawn any causal relationship and can only be used for hypothesis generation. Second, although we have adjusted for multiple covariates, some unmeasured and unknown covariates might exist and influence the findings. Third, the current findings might not be extrapolated to other racial and ethnic groups. Last but not the least, all participants in the current study were without cardiovascular disease and whether these findings can be extrapolated to those with cardiovascular disease is unknown.
In conclusion, the current study shows that in hypertensive patients without cardiovascular disease, 24h ABP appears to be better than OBP in reflecting the relationship between elevated BP and LV structural and functional alterations. In addition, there was difference in the association between 24h ABP and LV structural and functional alterations by sex.
The authors report no conflicts of interest in this work.
1. Liu LS, Wu ZS, Wang JG, et al. 2018 Chinese guidelines for prevention and treatment of hypertension-A report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182241. doi:10.11909/j.issn.1671-5411.2019.03.014
2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):30213104. doi:10.1093/eurheartj/ehy339
3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13e115. doi:10.1161/HYP.0000000000000065
4. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 20122015. Circulation. 2018;137(22):23442356. doi:10.1161/CIRCULATIONAHA.117.032380
5. Sorrentino MJ. The evolution from hypertension to heart failure. Heart Fail Clin. 2019;15(4):447453. doi:10.1016/j.hfc.2019.06.005
6. Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019;15(4):531541. doi:10.1016/j.hfc.2019.06.007
7. Cai A, Zhou D, Liu L, Zhou Y, Tang S, Feng Y. Age-related alterations in cardiac and arterial structure and function in hypertensive women and men. J Clin Hypertens. 2021;23(7):13221334. doi:10.1111/jch.14262
8. Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: action to control cardiovascular risk in diabetes blood pressure trial. Hypertension. 2015;66(6):11231129. doi:10.1161/HYPERTENSIONAHA.115.06236
9. von Jeinsen B, Vasan RS, McManus DD, Mitchell GF, Cheng S, Xanthakis V. Joint influences of obesity, diabetes, and hypertension on indices of ventricular remodeling: findings from the community-based Framingham Heart Study. PLoS One. 2020;15(12):e0243199. doi:10.1371/journal.pone.0243199
10. Upadhya B, Rocco MV, Pajewski NM, et al. Effect of intensive blood pressure reduction on left ventricular mass, structure, function, and fibrosis in the SPRINT-HEART. Hypertension. 2019;74(2):276284. doi:10.1161/HYPERTENSIONAHA.119.13073
11. Cao X, Broughton ST, Waits GS, Nguyen T, Li Y, Soliman EZ. Interrelations between hypertension and electrocardiographic left ventricular hypertrophy and their associations with cardiovascular mortality. Am J Cardiol. 2019;123(2):274283. doi:10.1016/j.amjcard.2018.10.006
12. Park CM, March K, Ghosh AK, et al. Left-ventricular structure in the Southall And Brent REvisited (SABRE) study: explaining ethnic differences. Hypertension. 2013;61(5):10141020. doi:10.1161/HYPERTENSIONAHA.111.00610
13. Poppe KK, Doughty RN, Gardin JM. Ethnic-Specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study. JACC Cardiovasc Imaging. 2015;8(6):656665. doi:10.1016/j.jcmg.2015.02.014
14. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 17 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):25492558. doi:10.1016/S0140-6736(17)32478-9
15. Lewington S, Lacey B, Clarke R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med. 2016;176(4):524532. doi:10.1001/jamainternmed.2016.0190
16. Li Z, Liu J, Shen J, et al. Sex-specific cardiac and vascular responses to hypertension in Chinese populations without overt cardiovascular diseases. Postgrad Med. 2020;133(2):181187. doi:10.1080/00325481.2020.1835037
17. Tadic M, Cuspidi C, Grassi G. The influence of sex on left ventricular remodeling in arterial hypertension. Heart Fail Rev. 2019;24(6):905914. doi:10.1007/s10741-019-09803-3
18. Guzik P, Schneider A, Piskorski J, et al. Sex differences in excess and reservoir arterial blood pressures as markers of phenotype. J Hypertens. 2019;37(11):21592167. doi:10.1097/HJH.0000000000002135
19. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):21912194. doi:10.1001/jama.2013.281053
20. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233270. doi:10.1093/ehjci/jev014
21. Cai A, Zhong Q, Liu C, et al. Associations of systolic and diastolic blood pressure night-to-day ratios with atherosclerotic cardiovascular diseases. Hypertens Res. 2016;39(12):874878. doi:10.1038/hr.2016.82
22. Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157163. doi:10.1016/S0140-6736(03)15268-3
23. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1991;18(5):12871294. doi:10.1016/0735-1097(91)90549-O
24. Savage DD, Levy D, Dannenberg AL, Garrison RJ, Castelli WP. Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol. 1990;65(5):371376. doi:10.1016/0002-9149(90)90304-J
25. Cuspidi C, Facchetti R, Bombelli M, et al. High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population. Hypertension. 2019;73(3):612619. doi:10.1161/HYPERTENSIONAHA.118.12114
26. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29(1):16. doi:10.1038/jhh.2014.36
27. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73(5):e35e66. doi:10.1161/HYP.0000000000000087
28. Huang QF, Yang WY, Asayama K, et al. Ambulatory blood pressure monitoring to diagnose and manage hypertension. Hypertension. 2021;77(2):254264. doi:10.1161/HYPERTENSIONAHA.120.14591
29. Melville S, Byrd JB. Out-of-office blood pressure monitoring in 2018. JAMA. 2018;320(17):18051806. doi:10.1001/jama.2018.14865
See original here:
Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... - April 13th, 2018 [April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health - May 12th, 2018 [May 12th, 2018]
- Ventricular septal defect - Wikipedia - June 21st, 2018 [June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... - July 7th, 2018 [July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... - July 17th, 2018 [July 17th, 2018]
- Ventricular Remodeling | Profiles RNS - July 24th, 2018 [July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia - August 20th, 2018 [August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) - September 24th, 2018 [September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... - November 25th, 2018 [November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com - December 25th, 2018 [December 25th, 2018]
- TIMI Study Group - LEADERSHIP - January 31st, 2019 [January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... - February 24th, 2019 [February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald - September 18th, 2019 [September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device - September 18th, 2019 [September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD - September 18th, 2019 [September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 18th, 2019 [September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD - September 18th, 2019 [September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News - September 18th, 2019 [September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News - September 18th, 2019 [September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily - September 22nd, 2019 [September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... - November 7th, 2019 [November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald - December 3rd, 2019 [December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance - December 3rd, 2019 [December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition - December 3rd, 2019 [December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press - December 3rd, 2019 [December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool - December 3rd, 2019 [December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD - December 3rd, 2019 [December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network - December 4th, 2019 [December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance - December 4th, 2019 [December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times - December 13th, 2019 [December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews - December 13th, 2019 [December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist - December 16th, 2019 [December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... - January 13th, 2020 [January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... - January 13th, 2020 [January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News - January 23rd, 2020 [January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor - January 23rd, 2020 [January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances - February 1st, 2020 [February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor - February 1st, 2020 [February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... - February 26th, 2020 [February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance - March 5th, 2020 [March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... - March 15th, 2020 [March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance - March 15th, 2020 [March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... - March 16th, 2020 [March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal - April 23rd, 2020 [April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel - June 12th, 2020 [June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor - June 12th, 2020 [June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor - June 12th, 2020 [June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... - June 23rd, 2020 [June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web - August 29th, 2020 [August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News - September 3rd, 2020 [September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... - September 3rd, 2020 [September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape - September 5th, 2020 [September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex - October 27th, 2020 [October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire - October 27th, 2020 [October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser - November 12th, 2020 [November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... - November 25th, 2020 [November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances - January 13th, 2021 [January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor - April 13th, 2021 [April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire - April 13th, 2021 [April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press - April 13th, 2021 [April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer - May 25th, 2021 [May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times - June 21st, 2021 [June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network - November 5th, 2021 [November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape - November 5th, 2021 [November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... - January 26th, 2022 [January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business - May 7th, 2022 [May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... - May 7th, 2022 [May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire - September 12th, 2022 [September 12th, 2022]